Clinical trials for Prostate cancer

151 currently recruiting clinical trials
Phase 2 Prostate cancer #NCT07005154 #2024-517653-27-00
Adenocarcinoma Metastatic Hormone-sensitive None Systemic Treatment-Naive
1 recruiting site
Astellas Pharma Développement mondial, Inc.
Phase 2 Prostate cancer #NCT07005154 #2024-517653-27-00
Adenocarcinoma Metastatic Castration-resistant None 1 Hormone therapy
Systemic Treatment-Naive
1 recruiting site
Astellas Pharma Développement mondial, Inc.
Phase 2 Prostate cancer #NCT06582628 #2023-510536-37-00
Adenocarcinoma Metastatic Castration-resistant None
1 recruiting site
Fundacion Oncosur
Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer #NCT05384626 #2024-514266-39-00
Locally Advanced Metastatic Metastatic Castration-resistant ALK 1 2 3 or more
AKT ATM BRAF BRCA 1/2 CDK12 CHEK 1/2 ESR FGFR HER2 HOXB13 KRAS G12C KRAS non G12C MET MSI/dMMR NRAS NTRK-1/2/3 PALB2 PIK3CA PTEN RET Systemic Treatment-Naive
4 recruiting sites
Nuvalent Inc.
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT06653777 #2024-512729-10-00
Locally Advanced Metastatic Metastatic Castration-resistant FGFR 1 2 3 or more
Systemic Treatment-Naive
6 recruiting sites
UNICANCER
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT04116541 #2023-510567-35-00
Locally Advanced Metastatic Metastatic Castration-resistant Other mutation 1 2 3 or more
Systemic Treatment-Naive
8 recruiting sites
Centre Léon Bérard
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT04116541 #2023-510567-35-00
Locally Advanced Metastatic Metastatic Castration-resistant BRAF 1 2 3 or more
Systemic Treatment-Naive
8 recruiting sites
Centre Léon Bérard
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer #NCT04116541 #2023-510567-35-00
Locally Advanced Metastatic Metastatic Castration-resistant ALK 1 2 3 or more
Systemic Treatment-Naive
8 recruiting sites
Centre Léon Bérard
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer #NCT04116541 #2023-510567-35-00
Locally Advanced Metastatic Metastatic Castration-resistant EGFR MET NTRK-1/2/3 RET ROS-1 Other mutation 1 2 3 or more
Systemic Treatment-Naive
8 recruiting sites
Centre Léon Bérard
Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer #NCT05732831 #2022-502645-99-00
Locally Advanced Metastatic Metastatic Castration-resistant MTAP 1 2 3 or more
Systemic Treatment-Naive
3 recruiting sites
Tango Therapeutics